RecruitingNCT07364526

Non-Invasive Preimplantation Genetic Screening for Aneuploidies and Clinical Outcomes in Egg Donation Patients

Non-invasive Preimplantation Genetic Screening (niPGTA) in Oocyte Donation Patients.


Sponsor

Instituto Bernabeu

Enrollment

164 participants

Start Date

Feb 26, 2026

Study Type

OBSERVATIONAL

Conditions

Summary

Preimplantation genetic testing for aneuploidies (PGT-A) is commonly used in IVF but requires embryo biopsy and shows limited benefit in egg donation cycles. Non-invasive PGT-A (niPGTA), based on the analysis of cell-free embryonic DNA in spent culture media, offers a promising biopsy-free alternative. This prospective, blinded study in egg donation cycles will evaluate whether niPGTA-detected aneuploidy is associated with implantation failure and pregnancy loss, assessing its potential clinical value as a non-invasive embryo selection tool.


Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 50 Years

Inclusion Criteria4

  • Women between 18 and 50 years old who are oocyte recipients.
  • Signed consent form
  • Transfer of a single blastocyst-stage embryo
  • Male with normal sperm FISH

Exclusion Criteria3

  • Uterine malformations
  • Abnormal karyotypes in either partner
  • Failure to sign informed consent

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Instituto Bernabeu

Alicante, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07364526


Related Trials